Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

This study suggests that frontal fibrosing alopecia is a highly inflammatory disease involving TH1 and JAK-STAT pathways, without reduced hair keratins, highlighting JAK-STAT signaling as a potential therapeutic target.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

In this study of women with frontal fibrosing alopecia, delgocitinib cream improved the molecular signature of lesions and demonstrated potential as a treatment, showing significant transcriptomic changes and some clinical improvements over 12 weeks compared to a cream vehicle.

This review analyzed recent studies and concluded that JAK inhibitors are effective for treating lichen planopilaris, though concerns about long-term safety remain and further research is needed.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.

This article examines the potential of using oral minoxidil as an adjuvant treatment for patients with severe alopecia areata who do not respond to increased doses of Janus kinase inhibitors, but provides no new clinical results.

This study reports that tofacitinib, a JAK inhibitor, may stabilize hair loss in patients with classic lichen planopilaris and frontal fibrosing alopecia, though hair regrowth was not robust.

This case report suggests that starting selective Janus kinase 1 inhibition may improve alopecia in a patient with rheumatoid arthritis who was not responding to TNF-α inhibitor therapy and corticosteroids.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

In a mouse study, JAK inhibitors like Jakafi and Xeljanz prevented alopecia areata and aided hair regrowth; similar effects were observed in three patients with the condition.

This review discusses the potential applications of JAK inhibitors in various dermatological conditions beyond atopic dermatitis, emphasizing gaps in evidence and therapeutic opportunities in the context of Chinese clinical practice, but reports no new clinical results.

This study observed that in a real-world pediatric setting, Janus kinase inhibitors led to improvements in scalp, eyebrow, and eyelash involvement in children with alopecia areata, with a generally favorable tolerability profile, though baseline imbalances and non-randomized treatment allocation limit causal conclusions and drug comparisons.

JAK inhibitors may reduce depression risk in alopecia areata patients.

In this study, researchers found that minoxidil sulfate enhances the anti-inflammatory effects of the JAK inhibitor baricitinib in alopecia areata, modulating inflammatory signals and preserving immune privilege features in human hair cells, which suggests potential benefits for combined therapy.

This paper reviews recent advancements in understanding hair follicle structure and the role of JAKs in hair growth, though it does not report new experimental findings.

In this study, researchers focused on the "bulge region" of hair follicles, identifying Janus kinases as key players in hair growth signaling, which could inform new therapies for hair restoration.

In this case study, an 11-year-old girl with severe alopecia areata experienced complete hair regrowth and unexpected white-to-black hair repigmentation after switching from baricitinib to ritlecitinib, suggesting that prolonged Janus kinase inhibition may aid both hair and pigment restoration in severe pediatric cases.

Infections and missed treatments trigger flares in alopecia areata patients on JAK inhibitors.

JAK inhibitors help regrow eyebrow and eyelash hair and improve anxiety and depression in some alopecia areata patients.

This study evaluated the use of JAK inhibitors in patients with alopecia areata episodes lasting at least eight years and found that while the overall therapeutic response was limited, a subset of patients achieved meaningful hair regrowth, suggesting these treatments as a viable option.

This review highlights the potential for JAK inhibitors to effectively treat inflammatory and autoimmune skin diseases by targeting the JAK-STAT signaling pathway, advocating for an integrated approach to enhance targeted therapy.

This study found that Janus kinase inhibitors significantly improve treatment outcomes for complex skin conditions like atopic dermatitis and alopecia areata, but their implementation requires careful safety considerations, including risk assessments for cardiovascular, malignant, and reproductive issues.

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.